Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon gamma-primed mesenchymal stromal cells
- Development stage
- Unknown
- Lead developer
- Emory University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Interferon gamma-primed mesenchymal stromal cells (γMSCs) are an experimental cell-based therapy developed by Emory University for the treatment of moderate-to-severe persistent asthma. The therapy consists of allogeneic bone marrow-derived mesenchymal stromal cells that have been pre-treated (primed) with interferon-gamma (IFN-γ) to enhance their immunomodulatory and anti-inflammatory potency. This priming process is intended to increase the cells' ability to suppress inflammatory responses and reduce airway hyperreactivity compared to unprimed mesenchymal stromal cells. The treatment is administered as a single intravenous infusion and is currently being evaluated in a Phase 1 clinical trial (NCT05035862) to assess safety, toxicity, and potential mechanisms of action in young adults with childhood-diagnosed asthma.
- Other names
- interferon gamma-primed bone marrow mesenchymal stromal cellsIFNγ-primed bone marrow MSCs
02
Targets
IDO1 (Indoleamine 2,3-dioxygenase 1)PDCD1 (Programmed cell death protein 1 receptor)IL10RA (Interleukin-10 Receptor)TGFBR (TGF-beta receptor)
Beyond the preview
Go deeper on interferon gamma-primed mesenchymal stromal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon gamma-primed mesenchymal stromal cells.